Desalegn Addis Mussie

Dr. Desalegn Addis Mussie


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
DMDesalegn Addis Mussie
Desalegn Addis Mussie
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
AKAbel Temeche Kassaw
Abel Temeche Kassaw
EMEsileman Abdela Muche
Esileman Abdela Muche
Objective: To ascertain the clinical impact, prevalence and associated determinants of delayed treatment intensification, defined as delaying the escalation of treatment plans for individuals with type 2 diabetes mellitus who fail to attain ideal glycaemic control, at the University of Gondar Comprehensive Specialised Hospital in Northwest Ethiopia. Design: A mixed-methods study. Setting: University of Gondar Comprehensive Specialised Hospital. Participants: 420 patients with type 2 diabetes mellitus with poor glycaemic control after the index date were included in this study. A simple random sampling technique was employed to select the required sample size. Data were collected retrospectively and entered into EpiData V.4.6 and exported to Stata V.14.2 for analysis. Method: Multivariable logistic regression was used to identify factors associated with delayed treatment intensification. A p value of 0.05 in the multivariable analysis was considered statistically significant. Qualitative data were collected through in-depth interviews with eight selected healthcare providers, and thematic analysis was undertaken to identify the underlying barriers to timely treatment intensification. Primary outcome: Delayed treatment intensification. Results: The prevalence of delayed treatment intensification was 51.4% (95% CI 46.6% to 56.2%), with a median delay of 14 months (IQR: 7.5–42 months) from the index date. Among those experiencing delayed treatment intensification, 43.1% developed new chronic diabetic complications, including retinopathy (18.1%), neuropathy (14.4%) and nephropathy (6.0%). Other complications (hypertension, stroke, heart failure and diabetic foot ulcer) accounted for 4.64% of the cases. Significant predictors of delayed treatment intensification included longer duration of diabetes (adjusted ORs (AOR) 1.68; 95% CI 1.13 to 2.5), presence of comorbidities (AOR 1.83; 95% CI 1.04 to 3.2) and use of cardioprotective medications (AOR 1.59; 95% CI: 1.04 to 2.43). The qualitative findings revealed additional barriers contributing to delayed treatment intensification, including financial limitations, insufficient patient awareness and non-adherence among patients. Additionally, healthcare provider-related factors, including professional fatigue and knowledge gaps, as well as health institution-related factors such as inadequate healthcare infrastructure. Conclusions: This study found a high prevalence of delayed treatment intensification (51.4%), associated with comorbidities, longer disease duration, low patient awareness, cardioprotective drug use and barriers related to the system and providers. To address these gaps, priorities should include strengthening patient education, scheduling regular reviews for high-risk patients and improving clinical decision support tools for timely treatment intensification. Enhancing healthcare infrastructure, such as medication supply and diagnostic services, and offering refresher training to reduce provider fatigue, are also crucial for improving the delivery of diabetes care.

5 March 2026 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
woretaw  sisayworetaw sisay
woretaw sisay
MAMuluken Adela Alemu
Muluken Adela Alemu
TMTilaye Arega Moges
Tilaye Arega Moges
SASisay Sitotaw Anberbr
Sisay Sitotaw Anberbr
DMDesalegn Addis Mussie
Desalegn Addis Mussie
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
Background: Despite prophylactic pharmacotherapy being ranked as the best intervention yet, poor treatment adherence tempers tuberculosis preventive therapy (TPT) efficacy. Objectives: This study aimed to investigate TPT non-adherence among household contacts and its determinants following the rollout of the 3HP regimen in northwest Ethiopia. Design: A facility-based multicenter retrospective study was conducted in selected hospitals of northwest Ethiopia from October 17 to February 21, 2024. Methods: Target populations were TPT-eligible household contacts (⩽15 years old) based on the national tuberculosis treatment guideline. Univariate and multivariate binary logistic regression model was fitted to identify potential predictors. p -Value < 0.05 was employed to adjudicate the significance level. Results: Among 494 household contacts (HHCs) enrolled in this study, 27.94% were non-adherent. Age (5–10 years: adjusted odds ratio (AOR) (95% CI): 1.92 (1.05–3.19); 10–15 years: AOR (95% CI): 2.04 (1.01–4.12)), parental status (AOR (95% CI): 1.87 (1.02–5.24)), comorbidity (AOR (95% CI): 2.92 (1.08–5.69)), poor nutritional status (AOR (95% CI): 1.30 (1.06–2.43)), adverse drug reactions (AOR (95% CI): 4.01 (1.03–8.20)), adherence support (AOR (95% CI): 1.56 (1.08–6.69)) and TPT regimen type (AOR (95% CI): 4.23 (1.85–6.53)) predicts non-adherence. Conclusion: Altogether, this study revealed a high level of non-adherence among HHCs in northwest Ethiopia, falling short of the national 2025/26 TPT targets. TPT should be accompanied by firm counseling and routine supervision to improve adherence.

1 February 2026 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
DMDesalegn Addis Mussie
Desalegn Addis Mussie
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
AKAbel Temeche Kassaw
Abel Temeche Kassaw
WZWoretaw Sisay Zewdu
Woretaw Sisay Zewdu
GTGetachew Yitayew Tarekegn
Getachew Yitayew Tarekegn
Chronic diseases such as diabetes, cardiovascular conditions, and arthritis often require lifelong pharmacotherapy. Medication side effects can negatively affect patients' quality of life and adherence. Understanding how patients cope with these side effects is essential for improving patient-centered care. This study aimed to explore the coping strategies used by patients with chronic diseases to manage medication-related side effects in Northwest Ethiopia. An interpretive phenomenological study was conducted in five hospitals in the Amhara region between May and August 2025. Forty-seven adults experiencing medication side effects were purposively selected. Data were collected through in-depth interviews, transcribed verbatim, and analyzed thematically using Open Code version 4.03. Four major themes and nine subthemes emerged. Patients coped with side effects by modifying medication use (stopping, reducing, or changing timing), relying on faith and positive thinking, seeking alternative treatments (e.g., herbal remedies or traditional healers), and obtaining support from healthcare providers, family, and friends. While self-modification of medication sometimes provided temporary relief, it posed potential risks. In contrast, support from healthcare providers and social networks enhanced adherence and psychological resilience. Patients in Ethiopia use diverse, culturally rooted strategies to cope with medication side effects. Some practices may compromise treatment effectiveness, highlighting the need for proactive, culturally sensitive interventions that combine patient education, spiritual support, and improved patient–provider communication to promote safe medication use, adherence, and overall well-being.

12 February 2026 in BMJ Open
Verified
Journal Article
Open access
GYGetachew Yitayew
Getachew Yitayew
FDFisseha Nigussie Dagnew
Fisseha Nigussie Dagnew
SWSamuel Agegnew Wondm
Samuel Agegnew Wondm
SASisay Sitotaw Anberbr
Sisay Sitotaw Anberbr
FTFasil Bayafers Tamene
Fasil Bayafers Tamene
TMTilaye Arega Moges
Tilaye Arega Moges
Objectives: To assess health-related quality of life (HRQoL), treatment satisfaction and associated factors among older adults with acute heart failure in Northwest Ethiopia. Design: Prospective, multicentre observational study. Setting: Three tertiary hospitals in Northwest Ethiopia provide secondary and tertiary care services. Participants: A total of 422 patients aged ≥60 years with a confirmed diagnosis of acute heart failure were consecutively enrolled between December 2024 and April 2025. Patients with unstable psychiatric conditions or advanced kidney disease were excluded. Outcome measures: HRQoL was assessed using the WHO Quality of Life – Brief Version questionnaire, and treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). Multiple linear regression identified factors associated with HRQoL and treatment satisfaction. Results: 95% of participants reported moderate HRQoL, and 3% reported poor HRQoL. Weight loss was positively associated with HRQoL (β=1.52; 95% CI 0.04 to 3.07; p=0.021), whereas asthma was negatively associated with HRQoL (β = –3.28; 95% CI 6.94 to 0.37; p=0.001). Regarding treatment satisfaction, 65% of patients were moderately satisfied, with notable concerns regarding medication safety and overall experience. Rural residents reported lower satisfaction than urban residents (β = –0.20; 95% CI 0.34 to 0.05; p=0.007). Patients with New York Heart Association (NYHA) class III had higher satisfaction (β=0.25; 95% CI 0.05 to 0.45; p=0.016). Effective hypertension management was linked to increased satisfaction (β=0.20; 95% CI 0.02 to 0.37; p=0.026), whereas coronary heart disease was associated with lower satisfaction (β = –0.40; 95% CI 0.64 to 0.88; p=0.012). Conclusions: Among older adults with heart failure in Northwest Ethiopia, 98% reported moderate to low HRQoL. Asthma and polypharmacy negatively affected HRQoL, whereas weight loss was positively associated with HRQoL. An NYHA class III status and well-managed hypertension improved treatment satisfaction, whereas rural residency and coronary heart disease were associated with lower satisfaction. These findings underscore the need for targeted interventions to enhance outcomes and QoL in this vulnerable population.

28 February 2026 in Sage Open Pediatrics
Verified
Journal Article
Open access
AKAbel Temeche Kassaw
Abel Temeche Kassaw
ETEliyas Addisu Taye
Eliyas Addisu Taye
DMDesalegn Addis Mussie
Desalegn Addis Mussie
GYGetachew Yitayew
Getachew Yitayew
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
Background: Ethiopia remains among the 5 countries with the highest under-five mortality, yet prospective multicenter data on pediatric intensive care unit (PICU) outcomes are limited. Objective: To determine the incidence and predictors of mortality among children admitted to PICUs in Eastern Amhara. Methods: A prospective observational study was conducted on 240 children admitted to tertiary-level PICUs between February and April 2025. Kaplan–Meier analysis estimated survival probabilities, and Cox proportional hazards regression identified independent predictors of mortality Results: Fifty-eight deaths (24.2%) occurred. Rural residence (AHR: 2.0, 95% CI: 1.2-3.5), the use of inotropic agents (AHR: 2.0, 95% CI: 1.2-3.5) consciousness level (GCS <8; AHR: 2.3, 95% CI: 1.2-4.4), presence of comorbidities (AHR: 1.9, 95% CI: 1.1-3.4) were associated increased mortality. Conclusion: PICU mortality was high, especially among rural children, those with severe neurological impairment, comorbidities, or requiring inotropes, emphasizing early identification and close monitoring of high-risk patients.

1 February 2026 in Sage Open Chronic Disease
Verified
Journal Article
Open access
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
DMDesalegn Addis Mussie
Desalegn Addis Mussie
TMTilaye Arega Moges
Tilaye Arega Moges
SWSamuel Agegnew Wondm
Samuel Agegnew Wondm
AKAbel Temeche Kassaw
Abel Temeche Kassaw
Background: Therapeutic inertia is a significant challenge to optimal blood pressure control, resulting in prolonged exposure to high blood pressure and increased cardiovascular risk, especially among older patients in low- and middle-income countries. Objectives: The current study assessed the impact of interventions by pharmacists on the time to antihypertensive treatment intensification among older patients with uncontrolled hypertension in Northwest Ethiopia. Design: A multicenter prospective cohort study was conducted from January to July 2025 in three tertiary hospitals in Northwest Ethiopia. Methods: A total of 422 older hypertensive patients with uncontrolled blood pressure were enrolled and followed up either in the pharmacist-led care or usual care. The interventions by pharmacists included recommendations for treatment intensification, medication review, adherence, and resolution of drug-related problems. The primary outcome was time to antihypertensive treatment intensification. Kaplan–Meier survival analysis and Cox proportional hazards regression were employed to evaluate the time-to-event outcomes and factors. Results: Patients receiving pharmacist-led care experienced significantly faster treatment intensification than those receiving usual care, with a median time of 28 days versus 63 days. A higher proportion of patients in the pharmacist-led group achieved treatment intensification within 30, 60, and 90 days. Faster treatment intensification (adjusted hazard ratio (AHR) 2.18) was independently linked to pharmacist-led care. The intervention group showed greater systolic and diastolic blood pressure reductions, as well as a higher percentage of patients who achieved blood pressure control at follow-up. In addition, higher baseline systolic blood pressure was linked to faster intensification of treatment. Conclusion: Pharmacist-led interventions significantly reduced therapeutic inertia by accelerating antihypertensive treatment intensification and improving blood pressure control. Integrating pharmacists into multidisciplinary hypertension care may represent an effective and scalable strategy to improve hypertension outcomes in resource-limited settings.